AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05235191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone tablets
Description: The intervention with the active drug (methadone) will start with the dose of 1 tablet (5 mg) twice a day (every 12 hours) and titrated on subsequent visits up to the maximum dose of 6 tablets a day (totaling 30 mg divided into 2 daily doses to facilitate therapeutic adherence).
Study NCT05235191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
Study NCT01504321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxonidine
Description: 0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
Study NCT01504321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated lactose powder
Study NCT02526069 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy
Description: An application based on Acceptance and Commitment Therapy
Study NCT04067362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food containing dietary fiber
Description: commercially available chicory root flour and chicory root fiber
Study NCT04067362 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: food containing dietary fiber
Description: commercially available chicory root flour and chicory root fiber
Study NCT02449239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vicinium
Description: Intravesical administration
Study NCT01945489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
Study NCT01945489 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
Study NCT01945489 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Normal saline
Description: Normal saline (placebo) injected into the detrusor.
Study NCT01550419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
Study NCT01550419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The smell and shape of placebo are the same as atorvastatin
Study NCT03323489 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Celiac Plexus Radiosurgery
Description: patients will receive a single radiation treatment of 25 Gy directed towards the celiac surgery, and at the physician's discretion also abutting tumor
Study NCT01275066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110 Weekly
Description: BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
Study NCT01275066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
Study NCT01275066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110 Every Other Week
Description: BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
Study NCT03455465 — intervention group
Intervention type: OTHER
Intervention: Community Health Worker Assessment
Description: Participants will be approached by a community health worker who will ask them to complete an assessment of needs and offer to enroll them in post-discharge services to help address the needs identified.
Study NCT02235779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transbronchial lung cryobiopsy
Study NCT01347437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive STEPS
Description: This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team-is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment B
Description: Days 2 and 15: Single oral dose of a matching placebo capsule of moxifloxacin.
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Treatment C
Description: Day 2: A single oral dose of 400 mg moxifloxacin capsule.
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment C
Description: Day 15: A single oral dose of a matching placebo capsule for moxifloxacin.
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment D
Description: Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
Study NCT02889211 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gambling Task
Study NCT04778826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphadenectomy
Description: radical bloc dissection of all mediastinal lymph node stations
Study NCT03634930 — intervention group
Intervention type: BEHAVIORAL
Intervention: observation
Description: Observation of growth, infant bodycomposition, 24h-drinkingvolume
Study NCT02630303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED-RL Phototherapy
Description: The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks.
Study NCT02630303 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mock Therapy
Description: Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks.
Study NCT01915173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
Study NCT01915173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose tablets
Study NCT01915173 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expanded Interview
Study NCT01915173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Interview
Study NCT01915173 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Interview
Study NCT02915653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational materials on a new diagnostic service
Description: Educational materials on a new diagnostic service
Study NCT05771259 — intervention group
Intervention type: OTHER
Intervention: Assessment of knowledge and behaviour
Description: Assessment of knowledge and behaviour
Study NCT02464202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stereolithography tooth replica
Description: Tooth replica will be made and used for preparing the receiving tooth socket during autotransplantation
Study NCT02262481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dydrogesterone
Study NCT02262481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01514695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
Study NCT01514695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
Study NCT01514695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 100mcg intravenously given in 2mL syringe at start of procedure
Study NCT01514695 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of saline (2ml)
Study NCT01521611 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Targeted radiotherapy
Description: Yttrium-90 labelled anti-CD66 monoclonal antibody.
Study NCT00843713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
Study NCT00843713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
Study NCT01404091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally
Study NCT01890772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Study NCT01915173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Interview
Study NCT04294602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.
Study NCT01890772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Study NCT01890772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT01890772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Study NCT02881996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV tylenol
Description: IV tylenol given scheduled in addition to standard PCA
Study NCT04294602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points.
Study NCT04294602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel Pressure Release
Description: MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, manuel pressure applied trigger point in neck and mactication muscles
Study NCT04294602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.
Study NCT02881996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No IV tylenol
Description: No additional IV Tylenol given
Study NCT02881996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: both groups receive as part of our standard postop pain protocol after all operations
Study NCT02881996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: both groups receive as part of our standard postop pain protocol after all operations
Study NCT00787189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Hearing Laser
Description: Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.
Study NCT00787189 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: inactive low level laser light therapy with no therapeutic output
Study NCT02502045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning Simulated Sunlight
Description: Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days
Study NCT02502045 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-therapeutic Red Light
Description: Non-therapeutic red light control at 5 lux will be used as the control condition
Study NCT03079895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive
Description: Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
Study NCT01517555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
Study NCT01517555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liraglutide
Description: Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
Study NCT01517555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
Study NCT01517555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
Study NCT03808298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.
Study NCT02530424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations
Study NCT02530424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration
Study NCT02530424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles
Study NCT02530424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
Study NCT01427088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CR Technology, TAMAS for repetitive TMS
Description: repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
Study NCT01517555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: One single dose of 1 g. Tablet
Study NCT01517555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paracetamol
Description: One single dose of 1 g. Tablet
Study NCT01425125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan in euvolemic hyponatremia
Description: This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
Study NCT03456232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Description: High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.
Study NCT03456232 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration
Description: Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.
Study NCT03755882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® DEFINE™ Vivid Style
Description: TEST Lens
Study NCT03755882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LACELLE™ Sparkling Brown
Description: CONTROL Lens
Study NCT01942174 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prevenar 13
Description: Vaccination at the beginning of the study (day 0)
Study NCT01942174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: Vaccination at the beginning of the study (day 0)
Study NCT01942174 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumo23 / Pneumovax
Description: Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company
Study NCT01942174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumo23 / Pneumovax
Description: Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company
Study NCT01942174 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate - Immediate
Description: concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
Study NCT01942174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate - Delay
Description: For period group, methotrexate is Initiated \& month after the antipneumococcal vaccination by prevenar 13
Study NCT04220944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.
Study NCT04220944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: The ablation area should covered at least two thirds the size of the nodules.
Study NCT04220944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.
Study NCT03221933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Somatropin Injection low dose group
Description: 0.23mg/kg /wk，inject for seven divided doses
Study NCT03221933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Somatropin Injection high dose group
Description: 0.46mg/kg /wk，inject for seven divided dose
Study NCT00387634 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBE vaccine for adults
Description: Serology blood draw.
Study NCT03781141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound closure
Description: Comparison of two wound closures
Study NCT02288572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus plantarum PCS 26
Description: Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.
Study NCT02288572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking dietary supplement on a daily basis for 3 months.
Study NCT03747575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSTT1041A
Description: Participants will receive subcutaneous (SC) MSTT1041A
Study NCT03747575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC placebo
Study NCT02036892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling with smartphone
Description: Lifestyle counseling with health promoting smartphone software
Study NCT03781141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound closure
Description: Comparison of two wound closures
Study NCT02036892 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Lifestyle counseling
Study NCT02279888 — intervention group
Intervention type: DEVICE
Intervention: CardioMEMS HF System
Description: Pulmonary artery pressure sensor